Daiichi Sankyo US Executive and Leadership Team

Dakota Micanopy, the Chief Executive Officer at Daiichi Sankyo US, directs the overarching strategic vision for the organization. Micanopy architects long-term growth initiatives while overseeing the integration of innovative pharmaceutical research into the North American market. By aligning internal resources with global corporate objectives, the Chief Executive Officer ensures the company maintains a competitive edge in the oncology and specialty medicine sectors. Micanopy fosters collaboration across all departments to accelerate the delivery of life-saving therapies to patients. This leadership role involves constant engagement with the Board to refine operational priorities and drive sustainable financial performance. Through rigorous oversight of the U.S. subsidiary, Dakota Micanopy secures the company's position as a leader in pharmaceutical manufacturing. Micanopy champions a culture of accountability, ensuring every business unit adheres to the highest standards of scientific excellence and operational efficiency while expanding the reach of the company's diverse product portfolio.

Erin Mulrooney, the Senior Director, Chief of Staff, Early Development Oncology at Daiichi Sankyo US, manages the strategic execution of early-stage clinical programs. Mulrooney coordinates cross-functional teams to streamline the transition of oncology assets from research into clinical development. By optimizing resource allocation, the Senior Director, Chief of Staff, Early Development Oncology ensures that high-potential therapies move efficiently through the pipeline. Erin Mulrooney facilitates communication between scientific researchers and executive leadership to maintain alignment with the company's broader oncology mission. This role involves monitoring clinical milestones and adjusting project timelines to meet rigorous regulatory requirements. Mulrooney drives the operational success of early development initiatives, ensuring that the company remains at the forefront of cancer treatment innovation. Through meticulous planning and project management, the Senior Director, Chief of Staff, Early Development Oncology supports the rapid advancement of novel compounds, ultimately strengthening the company's impact on patient outcomes across global markets.

Brittany Pilcher, the Global Compliance & Risk Management Chief of Staff at Daiichi Sankyo US, directs the framework for regulatory adherence and enterprise risk mitigation. Pilcher architects comprehensive policies that safeguard the company against operational and legal vulnerabilities. By overseeing the implementation of global compliance standards, the Global Compliance & Risk Management Chief of Staff ensures that all pharmaceutical activities meet strict industry regulations. Brittany Pilcher coordinates with international teams to harmonize risk management strategies across diverse geographic regions. This leadership role involves identifying potential threats to the business model and developing proactive solutions to maintain organizational integrity. Pilcher drives the integration of ethical practices into daily operations, ensuring that the company upholds its reputation for accountability. Through continuous monitoring and assessment, the Global Compliance & Risk Management Chief of Staff protects the company's assets and supports the sustainable growth of the pharmaceutical business, reinforcing the commitment to excellence in every facet of the organization.

Simon King, the Chief People Officer at Daiichi Sankyo US, directs the human capital strategy to support the company's pharmaceutical mission. King architects talent acquisition and development programs that attract top-tier scientific and operational professionals. By fostering an inclusive and high-performance culture, the Chief People Officer ensures that the workforce remains aligned with the company's core values of integrity and innovation. Simon King oversees organizational design and employee engagement initiatives to maximize productivity across all departments. This leadership role involves collaborating with other C-suite executives to build a resilient workforce capable of navigating the complexities of the pharmaceutical industry. King drives the implementation of performance management systems that reward excellence and support professional growth. Through strategic workforce planning, the Chief People Officer ensures that the company possesses the necessary expertise to achieve its long-term objectives. King maintains a focus on employee well-being and professional development, which directly contributes to the overall success and stability of the organization.